Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus UROPLUS SS.
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic